| CASE REPORT |
|
| Year : 2021 | Volume
: 15
| Issue : 1 | Page : 31-35 |
|
|
Effects of montelukast on clinical manifestations of coronavirus infection: A clinical observation among six patients
Ram B Singh1, Ghizal Fatima2, Saibal Chakravorty3
1 Department of Cardiology, Halberg Hospital and Research Institute, Moradabad, Uttar Pradesh, India
2 Department of Cardiology, Era's Lucknow Medical College, Lucknow, Uttar Pradesh, India
3 Department of Cardiology, Metro Multispeciality Hospital, Noida, Uttar Pradesh, India
Correspondence Address:
Dr. Ghizal Fatima
Era's Lucknow Medical College, Lucknow, Uttar Pradesh
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/upjimi.upjimi_3_22
|
|
|
Montelukast is an antiviral agent and anti-inflammatory agent used in the treatment of pro-inflammatory pulmonary diseases. Since coronavirus infection disease 2019 (COVID-19) involves mainly lung in majority of the patients, it may have a possible benefit among these patients. This report aims to emphasize about the role of montelukast in COVID-19 patients. After verbal consent and clearance from the ethics committee, all the patients (n = 6) presenting with common cold, fever, cough, and breathlessness, who were administered montelukast, were considered for entry to this study. The diagnosis of COVID-19 was confirmed via a positive reverse transcription-polymerase chain reaction test among all the patients. All the patients were given standard treatment including hydroxychloroquine 200 mg twice daily day 1 and then 200 mg daily for 5 days, azithromycin 250–500 mg twice daily for 7 days, Vitamin C 500 mg daily, and Zincovit 1 tablet daily for about 3 weeks. Clinical, radiological, and blood examinations were done in all the patients included in this report. All the patients were adults between 34 and 70 years, 3 females, and presented with fever, cough, breathlessness, and body ache simulating a respiratory tract viral infection. They were initially treated with levocetirizine and montelukast 10–20 mg twice or thrice daily, depending upon clinical status of these patients. Those patients who had lower oxygen saturation below 90% (n = 2) were also administered oxygen and cortisone (n = 2) for possible benefit. Only one patient was hospitalized and one was on noninvasive ventilation for 5 days due to lower oxygen saturation below 70%. All patients recovered. All patients received standard treatment for COVID-19, hence it is not clear that which treatment had provided the benefit. Since all patients received montelukast and only one was hospitalized, it poses the possibility that the role of montelukast should be examined in a large number of patients in phase II and phase III trials.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
